We are live on ! Find out more
OREX

Orexigen Therapeutics
OREX

Delisted

OREX was delisted on the 3rd of April, 2018.

121 hedge funds and large institutions have $164M invested in Orexigen Therapeutics in 2015 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 31 increasing their positions, 44 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

8% less funds holding

Funds holding: 132 → 121 (-11)

11.38% less ownership

Funds ownership: 77.08% → 65.69% (-11%)

30% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 44

46% less call options, than puts

Call options by funds: $961K | Put options by funds: $1.77M

59% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 22

67% less capital inflows, than outflows

Capital inflows: $20.7M | Capital outflows: $62.8M

Holders
121
Holders Change
-11
Holders Change %
-8.33%
% of All Funds
3.17%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
9
Increased
31
Reduced
44
Closed
22
Calls
$961​K
Puts
$1.77​M
Net Calls
-⁠$806​K
Net Calls Change
-⁠$411​K

OREX Hedge Fund Activity: Q4 2015 in Review

121 of the 3,823 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics (OREX) for Q4 2015, worth a combined $164M — down 30% from $236M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of OREX and 9 opened new positions — a net loss of 13 holders — while 44 trimmed existing stakes and 31 added.

The largest buyer was Foresite Capital Management II, adding an estimated $4.77M. The largest seller was State Street, cutting an estimated $24.1M.

  • 121 institutional investors held Orexigen Therapeutics (OREX) as of Q4 2015, down from 132 in Q3 2015.
  • Funds reported $164M of Orexigen Therapeutics stock for Q4 2015, down 30% quarter-over-quarter.
  • 9 funds opened new Orexigen Therapeutics positions in Q4 2015 and 22 closed out, a net change of -13 holders.
  • The largest Orexigen Therapeutics buyer in Q4 2015 was Foresite Capital Management II, an estimated $4.77M added.
  • The largest Orexigen Therapeutics seller in Q4 2015 was State Street, an estimated $24.1M sold.

Based on aggregated 13F filings for Q4 2015.